Developing and Manufacturing Attenuated Live Bacterial Vaccines - Specific requirements must be met during preclinical and clinical development, as well as manufacturing and release testing of LBVs. -


Developing and Manufacturing Attenuated Live Bacterial Vaccines
Specific requirements must be met during preclinical and clinical development, as well as manufacturing and release testing of LBVs.

BioPharm International Supplements

Regulatory Hurdles

In addition to regulations governing all vaccines, LBVs face additional regulatory hurdles. First, they must achieve the right balance between safety and immunogenicity. Additional issues include the potential for genetic reversion to partial or full pathogenicity, gene transfer into and out of the vaccine cells, and the potential risks for humans and the environment. For many vaccine candidates, the appropriate balance of attenuation and immunogenicity could not be met, and development of such candidates was consequently discontinued at an early stage of clinical evaluation. For the trivalent oral polio vaccine, which has been licensed for decades, it is known that reversion to virulence occurs quite often in the gastrointestinal tract of vaccinated individuals. This reversion to wildtype is a common cause of disease when a virus is shed and transmitted to nonimmune household contacts. Hence, these safety issues have to be addressed very carefully during preclinical and clinical development.

Determining Safety and Efficacy

In the case of Ty21a, safety and efficacy of the vaccine were demonstrated in a large number of clinical trials, with over 500,000 vaccinated children and adults in the US, Europe, Africa, Latin America, and Asia. Excellent tolerability and an overall protective efficacy of 67–80% were demonstrated for up to seven years in large field trials.5 The safety and tolerability profile of Ty21a was further confirmed in more than 200 million vaccinees during its more than 25-years of use worldwide. Recent postmarketing surveillance has identified only mild and infrequent adverse events associated with Ty21a. From 1990 to 2000, more than 38 million people were vaccinated with Ty21a with only 743 spontaneous reports of adverse events, an incidence of 0.002%. The most common adverse events reported with Ty21a were mild and transient gastrointestinal disturbances, followed by general symptoms such as pyrexia.

As mentioned above, the most important safety feature is to demonstrate that the vaccine strain is unable to revert to a virulent phenotype during production, inside the human body and after potential excretion of the vaccine strain, if applicable. For Ty21a, reversion to virulence has not been observed in vitro or in vivo during the more than 30 years since the strain was developed. No mutations were found in master and working seed lots produced over a 25-year period in genetic stability studies, nor was any reversion found in clinical trials. Clinical trials have also shown either a limited and transient level or a complete lack of shedding in the stools of volunteers depending on the administered dose of Ty21a. With a 10-fold overdose, mainly on day one post-vaccination, a low rate of excretion was observed. Further studies showed a lack of fecal excretion of Ty21a upon administration of the commercial formulation. The reason for the low excretion rate is probably the limited ability of the vaccine strain to proliferate in vivo. However, if there is excretion, additional studies need to be performed. In the case of Ty21a, these included an analysis of vaccine strain transmission to household contacts, which was not observed for Ty21a. Furthermore, Ty21a demonstrated a limited ability to survive in the environment because of its auxotrophy and reduced stress resistance, therefore not posing environmental risks.

The clinical program was somewhat different for CVD 103-HgR. For V. cholerae, a human challenge model exists. This means that after vaccination, humans can be infected intentionally with wildtype, fully virulent V. cholerae bacteria to determine whether the vaccine is indeed efficacious against infection and disease. In the volunteer challenge model, significant efficacy of CVD 103-HgR against wildtype V. cholerae challenge infection was demonstrated in North American adults as early as eight to 10 days after vaccination and for at least six months.10 Hence, oral vaccination with CVD 103-HgR is highly suitable to elicit protective immunity in North Americans, as shown in trials that are comparatively easy to perform. However, challenge trial results in North American adults may have limited relevance for the vaccines' protective efficacy in cholera-endemic areas of the world. Hence, a field trial was performed in Indonesia with CVD 103-HgR. Unfortunately, protective efficacy of CVD 103 HgR could not be demonstrated in this field trial. More than 60,000 children and adults were given either vaccine or placebo. However, cholera was virtually absent in Indonesia after initiating the clinical trial, and therefore, there were almost no cholera cases in the vaccine and the placebo group. This made it almost impossible to calculate a protective efficacy for the vaccine in this particular setting. This exemplifies the challenges vaccine field trials can pose.

In many controlled studies and after a decade of postmarketing experience, CVD 103-HgR has been shown to be safe and well tolerated. In diverse populations, no adverse reactions occurred significantly more often in vaccinees than in placebo recipients.10

blog comments powered by Disqus



Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here